RPH-104

Phase 3Biologic

UUnknown Sponsor

RPH-104 is one of 9 biologic programs targeting Familial Mediterranean Fever. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Familial Mediterranean FeverActive, not recruiting

PericarditisActive, not recruiting

Familial Mediterranean FeverPhase 2

Active, not recruiting

PericarditisPhase 3

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Pericarditis

#DrugCompanyPhaseTrials

Colcrys

Jazz Pharmaceuticals

Approved

6 2

Bayer Aspirin

Bayer

Approved

1 3

Epidiolex

Jazz Pharmaceuticals

Approved

—4

Kineret

SSwedish Orphan Biovitrum

Phase 3

4 5

RPH-104

UUnknown Sponsor

Phase 3

3 6

Cardiolrx

CCardiol Therapeutics Inc.

Phase 3

2 7

KPL-387

KKiniksa Pharmaceuticals International, plc

Phase 2

2 8

VTX2735

ZZomagen Biosciences Ltd.

Phase 2

1 9

Spikevax

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

Familial Mediterranean Fever

NCT05190991

Clinical

Trials by Indication[1]

Pericarditis3 trials

Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis

Active, not recruiting·UUnknown Sponsor·Phase 3·NCT05673902·17 enrolled

Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis

Suspended·RR-Pharm Overseas, Inc.·Phase 2/3·NCT05107934·80 enrolled

Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis

Completed·UUnknown Sponsor·Phase 2/3·NCT04692766·20 enrolled

Familial Mediterranean Fever2 trials

Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine

Active, not recruiting·UUnknown Sponsor·Phase 2·NCT05092776·84 enrolled

Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

Recruiting·UUnknown Sponsor·Phase 2·NCT05190991·60 enrolled

Efficacy and Safety1 trial

Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

Withdrawn·UUnknown Sponsor·Phase 3·NCT05432960

Acute1 trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack

Terminated·RR-Pharm·Phase 2·NCT04067492·47 enrolled

Tics1 trial

Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects

Completed·RR-Pharm·Phase 1·NCT02667639·35 enrolled

4 more indications

Intravenous Administration1 trial

Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers

Completed·UUnknown Sponsor·Phase 1·NCT07206043·130 enrolled

Severe Acute Respiratory Syndrome1 trial

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

Completed·UUnknown Sponsor·Phase 2/3·NCT04380519·372 enrolled

Schnitzler syndrome1 trial

Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome

Withdrawn·RR-Pharm Overseas, Inc.·Phase 2·NCT04213274

Myocardial Infarction1 trial

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

Completed·RR-Pharm Overseas, Inc.·Phase 2·NCT04463251·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for RPH-104. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RPH-104 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RPH-104. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unknown Sponsor company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: UUnknown Sponsor

RPH-104

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Pericarditis3 trials

Familial Mediterranean Fever2 trials

Efficacy and Safety1 trial

Acute1 trial

Tics1 trial

Intravenous Administration1 trial

Severe Acute Respiratory Syndrome1 trial

Schnitzler syndrome1 trial

Myocardial Infarction1 trial

References

Drug Info

Quick Facts

Related News